Health & Medicine Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health & Medicine Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Anthrax
$3.5M grant from U.S. government used for drug to treat anthrax exposure
October 27th, 2003
Elusys Therapeutics, Inc., has received an additional $3.5 million from the U.S. Department of Defense for the further development of its drug to remove anthrax toxin from the bloodstream. "The support from the Department of Defense allows us to make development of our unique anthrax drug, ETI-205, a top priority," said Stephen Sudovar, president and CEO of Elusys. "This funding enables us to complete the last phases of our efficacy studies and to scale up production in preparation for human safety studies." Elusys is developing a heteropolymer (HP) drug to remove anthrax toxin from the bloodstream. "The toxin is the component of anthrax that can...
Source: Health & Medicine Week (2003-10-27)
|
